SCHEMBL6741197

SCHEMBL6741197

CC(C)C[C@H](N)C(=O)N[C@H]1CCN(S(=O)(=O)c2cc(Cl)c(OC3CCNCC3)c(Cl)c2)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 14/20 0.52
CACNA1B Q00975 1/20 0.40
NPC1 O15118 2/20 0.37
RAB9A P51151 1/20 0.37
ATM Q13315 1/20 0.37
HTR1A P08908 1/20 0.36
CYP2D6 P10635 1/20 0.36
DRD2 P14416 1/20 0.36
HTR1D P28221 1/20 0.36
HTR2C P28335 1/20 0.36
HTR1F P30939 1/20 0.36
HTR2B P41595 1/20 0.36
HTR6 P50406 1/20 0.36
CYP3A43 Q9HB55 1/20 0.36
MMP2 P08253 1/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6739733 0.96 UTS2R (0.47) UTS2RCACNA1BNPC1RAB9AATM
SCHEMBL6741282 0.90 UTS2R (0.58) UTS2RCACNA1BNPC1RAB9AATM
SCHEMBL6741883 0.85 UTS2R (0.53) UTS2RCACNA1BMMP2SMN1; SMN2
SCHEMBL6744737 0.85 UTS2R (0.53) UTS2RCACNA1BMMP2SMN1; SMN2
SCHEMBL6609947 0.84 UTS2R (0.58) UTS2RCACNA1BNPC1RAB9AATM
SCHEMBL6742628 0.83 UTS2R (0.70) UTS2RCACNA1BHTR1ACYP2D6DRD2
SCHEMBL6744784 0.83 UTS2R (0.70) UTS2RCACNA1BHTR1ACYP2D6DRD2
SCHEMBL6741196 0.83 UTS2R (0.48) UTS2RNPC1RAB9AATMHTR1A
SCHEMBL6093548 0.83 UTS2R (0.39) UTS2RCACNA1BSMN1; SMN2
SCHEMBL6093953 0.82 UTS2R (0.48) UTS2RHTR2CPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152692-A1 Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders SMITHKLINE BEECHAM CORPORATION 2004-08-05 US claimed
US-20040152692-A1 Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders SMITHKLINE BEECHAM CORPORATION 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152692-A1 Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders UTS2R, PLAUR, SERPINE1 UTS2R 1/4885CACNA1B 4026/4885NPC1 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.